Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
June 12, 2022 05:30 ET
|
Novartis Pharma AG
In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after more than...
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
May 27, 2022 18:58 ET
|
Novartis Pharma AG
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah...
AGC Biologics Invests in New Viral Vector Suspension Capabilities at U.S. Cell & Gene Hub
May 17, 2022 22:03 ET
|
AGC Biologics
SEATTLE, May 17, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector...
Cell and Gene Therapy Market Size, Growth, Trends [2022] | Global Industry Share, Key Players, Recent Developments, Type & Application, Challenges & Restraints, Revenue, Stakeholders and Forecast Research | Market Reports World
May 09, 2022 01:36 ET
|
Market Reports World
Pune, May 09, 2022 (GLOBE NEWSWIRE) -- Global Cell and Gene Therapy Market Size 2022 research report provides an in-depth analysis of market size, share, growth, trends, and forecast. The Cell and...
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
March 25, 2022 08:03 ET
|
Novartis Pharma AG
Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial...
Almac Pharma Services Expands Its Unique Ultra-Low Temperature Solutions for Advanced Therapy Medicinal Products
March 14, 2022 12:31 ET
|
Almac Group
CRAIGAVON, Northern Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Almac Pharma Services, a member of the Almac Group providing innovative pharmaceutical development, manufacture and commercial...
POMSnet Falcon Dives Into Pharma and Biotech GMP Facilities Across the Globe
January 04, 2022 09:00 ET
|
POMS
HERNDON, Va., Jan. 04, 2022 (GLOBE NEWSWIRE) -- POMS Corporation releases POMSnet Falcon 2021.2 MES Dashboard and Analytics. POMSnet Falcon is perched to become the GMP facility standard for...
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
December 22, 2021 02:00 ET
|
Novartis Pharma AG
There are no currently approved therapies impacting disease progression for the up to 8 million people suffering from geographic atrophy (GA)1,2 Acquisition will add GT005 to the Novartis portfolio,...
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
December 13, 2021 14:45 ET
|
Novartis Pharma AG
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as foundation for various investigational CAR-T therapies Early data from first-in-human dose-escalation...
Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
August 24, 2021 01:15 ET
|
Novartis Pharma AG
Phase III BELINDA study did not meet primary endpoint of event-free survival for patients with aggressive B-cell non-Hodgkin lymphoma who had primary refractory disease or who relapsed within 12...